

Optimal COVID-19 testing strategy on limited resources

Onishi Tatsuki^{1,2,3¶}, Honda Naoki^{4, 5,6¶*}, Yasunobu Igarashi^{7,8*}

¹ Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Yoshidakonoecho, Sakyo, Kyoto, Japan

² Department of Anesthesiology and Pain Clinic, Juntendo University Shizuoka Hospital, Izunokuni, Shizuoka, Japan

³ Department of Anaesthesiology, Tokyo Metropolitan Bokutoh Hospital, Kotobashi, Sumida, Tokyo, Japan

⁴ Laboratory for Data-driven Biology, Graduate School of Integrated Sciences for Life, Hiroshima University, Higashihiroshima, Hiroshima, Japan

⁵ Theoretical Biology Research Group, Exploratory Research Center on Life and Living Systems (ExCELLS), National Institutes of Natural Sciences, Okazaki, Aichi, Japan

⁶ Laboratory of Theoretical Biology, Graduate School of Biostudies, Kyoto University, Yoshidakonoecho, Sakyo, Kyoto, Japan

⁷ E2D3.org, izumi-cho, Kokubunji, Tokyo, Japan

⁸ Center for Research on Assistive Technology for Building a New Community, Nagoya Institute of Technology, Nagoya, Aichi, Japan

* Corresponding author

E-mail: yasunobu.igarashi@gmail.com

¶* Co-corresponding author

E-mail: nhonda@hiroshima-u.ac.jp

¶These authors contributed equally to this work.

27 **Abstract**

28 The last three years have been spent combating COVID-19, and governments have been seeking optimal
29 solutions to minimize the negative impacts on societies. Although two types of testing have been performed
30 for this—follow-up testing for those who had close contact with infected individuals and mass-testing of
31 those with symptoms—the allocation of resources has been controversial. Mathematical models such as the
32 susceptible, infectious, exposed, recovered, and dead (SEIRD) model have been developed to predict the
33 spread of infection. However, these models do not consider the effects of testing characteristics and resource
34 limitations. To determine the optimal testing strategy, we developed a testing-SEIRD model that depends on
35 testing characteristics and limited resources. In this model, people who test positive are admitted to the
36 hospital based on capacity and medical resources. Using this model, we examined the infection spread
37 depending on the ratio of follow-up and mass-testing. The simulations demonstrated that the infection
38 dynamics exhibit an all-or-none response as infection expands or extinguishes. Optimal and worst follow-up
39 and mass-testing combinations were determined depending on the total resources and cost ratio of the two
40 types of testing. Furthermore, we demonstrated that the cumulative deaths varied significantly by hundreds
41 to thousands of times depending on the testing strategy, which is encouraging for policymakers. Therefore,
42 our model might provide guidelines for testing strategies in the cases of recently emerging infectious
43 diseases.

44

45

46 **1 Introduction**

47 The Coronavirus disease 2019 (COVID-19) emerged in Wuhan, China, raising concerns regarding global
48 healthcare [1,2]. By April 2020, the COVID-19 Alpha variant pandemic had infected 5.5 million people, and
49 350,000 people had died, owing to its high aerosol transmission ability and the lack of specific treatment in
50 the early stages [3]. Medical resources in hospitals were primarily used to treat COVID-19 patients [1,2]. As
51 of April 2020, approximately 10% of hospital beds, or 10–20% of ICU beds were occupied with COVID-19
52 care [3–5]. Moreover, in May 2020, the COVID-19 Beta variant emerged. The society needed to be updated
53 about the variant of concern (VOC) such as the Beta, Gamma, Delta, and Omicron variants every time a new
54 variant emerged [6–8].

55 To minimize the number of deaths, society must be aware of the advantages and disadvantages of
56 COVID-19 testing [9]. From an individual perspective, testing has advantages in that asymptomatic infected
57 individuals can be detected and prepared for symptomatic treatment, whereas from a societal perspective,
58 testing prevents secondary infections, expecting a reduction in the number of deaths [10–12]. The Alpha
59 variant pandemic in April 2020, in which no specific treatment was established and testing characteristics,
60 that is, sensitivity and specificity, were unknown, illustrates the drawbacks of testing, particularly in the
61 early pandemic stage. From an individual perspective, the testing result had no impact on medical care
62 because there was no specific treatment, but from a societal perspective, testing was performed aimlessly,
63 and people were uncertain about the testing outcomes, resulting in the wastage of medical and human
64 resources. Therefore, policymakers must consider the testing characteristics when determining the volume of
65 testing at each early stage of an emerging VOC.

66 The testing policies to minimize the number of deaths in the early stages of the COVID-19 Alpha
67 variant pandemic were controversial [7,10,11,13,15–20], and the controversy was centered on the two
68 extreme policies for balancing the medical supply and demand: mass-testing and no-testing [21]. According
69 to the mass-testing policy, everyone must be tested for public health, regardless of their symptoms [22–24].
70 The mass-testing policy assumes that testing and hospitalization of asymptomatic patients are important for
71 reducing the overall death rate even in the absence of a specific treatment. Conversely, the no-testing policy
72 claims that testing must be limited to symptomatic patients [21]. According to the no-testing policy,
73 asymptomatic patients cannot expect to benefit from mass-testing in the absence of a specific treatment.
74 Despite differences in these two policies' assumptions, they both support testing on people with symptoms.
75 However, these approaches disagree regarding the size of the tested asymptomatic population.

76 What testing strategy is most practical for minimizing the number of deaths? There are two testing
77 strategies for people without symptoms: follow-up-testing-dominant strategy, which follows up and tests the
78 exposed population, and mass-dominant testing strategy, which randomly tests the infected population.
79 Uncertainty about how follow-up and mass-testing of asymptomatic populations will affect the number of
80 deaths and determine the worst and optimal outcomes, particularly in the early stages of emerging VOC in
81 the future, remains a challenge [7,10,11,13,15–20].

82 In this study, we developed a testing-SEIRD model, aiming to evaluate a testing strategy that
83 combines follow-up and mass-testing in terms of minimizing the number of deaths during the early stages of
84 the emerging VOC. The testing-SEIRD model considers the testing characteristics, testing strategies,
85 hospitalized subpopulation, and the amount of medical resource [25]. Using this model, we examined the
86 optimal and worst testing strategies under the assumption that medical resources are both infinite and finite.
87 We found that the optimal testing strategy significantly depends on the cost ratio between mass and follow-
88 up testing. Therefore, this study provides insights into how to minimize the number of deaths in the absence
89 of a specific treatment during the early stages of a pandemic.
90

91 **2 Model**

92 To examine the impact of testing on the infection population dynamics, we developed a novel model by
93 incorporating a hospitalized subpopulation, testing strategy, and testing characteristics into the classical
94 SEIRD model. Generally, the subpopulation susceptible dynamics, exposed, infectious, recovered, and dead
95 people best summarize the SEIRD model (Fig. 1A) as follows:

$$\frac{dS}{dt} = -\frac{bIS}{N}, \#(2.1)$$


$$\frac{dE}{dt} = \frac{bIS}{N} - gE, \#(2.2)$$

$$\frac{dI}{dt} = gE - (r + d)I, \#(2.3)$$

$$\frac{dR}{dt} = rI, \#(2.4)$$

$$\frac{dD}{dt} = dI, \#(2.5)$$

96 where S , E , I , R , and D indicate the populations of susceptible, exposed, infectious, recovered, and dead
97 people, respectively; N indicates the total population, that is, $N=S+E+I+R$; b indicates the exposure rate,
98 which reflects the level of social activity; and g , r , and d indicate the transition rates among the
99 subpopulations. In this model, the recovered population is assumed to acquire permanent immunity,
100 indicating that they will never be infected.



101

102 **Figure 1: Schematic of the classical SEIRD and testing-SEIRD models**

103 (A) Classical SEIRD model: An infectious population “I” exposes a susceptible population “S” at a rate inversely
 104 proportional to the infectious population. The exposed population “E” becomes infectious “I.” The infected population
 105 finally recovers “R” or is dead “D.” (B) Testing-SEIRD model: The population is divided into two subpopulations;
 106 inside and outside the hospital. The exposed “E_o” and the infectious population outside “I_o” are hospitalized if evaluated
 107 as positive after testing. A susceptible population “S_h” remains at the hospitals. The black lines indicate population
 108 transitions, regardless of the capacity effect. The blue lines indicate population transition, considering the capacity
 109 effect. Transitions from “E_o” to “E_h” and “I_o” to “I_h” are categorized as hospitalized.

110

111 To incorporate the testing characteristics and testing strategies into the classical SEIRD model, we
 112 divided the population into outside and inside of the hospital (Fig. 1B). The dynamics of the population
 113 outside the hospitals are described using the following:

$$\frac{dI_o}{dt} = gE_o - (r_o + d_o)I_o - mSeI_oH(C - N_h), \#(2.8)$$

$$\frac{dR_o}{dt} = r_oI_o, \#(2.9)$$

$$\frac{dD_o}{dt} = d_oI_o, \#(2.10)$$

114 and those inside hospitals are described using the following:

$$\frac{dS_h}{dt} = -\frac{bI_hS_h}{N_h} + uE_h + aS_h, \#(2.11)$$

$$\frac{dE_h}{dt} = \frac{bI_hS_h}{N_h} - (u + g)E_h + f(1 - Sp)E_oH(C - N_h), \#(2.12)$$

$$\frac{dI_h}{dt} = gE_h - (r_h + d_h)I_h + mSeI_oH(C - N_h), \#(2.13)$$

$$\frac{dR_h}{dt} = r_hI_h, \#(2.14)$$

$$\frac{dD_h}{dt} = d_hI_h, \#(2.15)$$

115 where X_o and X_h indicate each population outside and inside the hospital ($X \in \{S, E, I, R, D, N\}$), respectively;
116 N_o and N_h indicate the total populations outside and inside hospitals, respectively (that is, $N_o = S_o + E_o + I_o + R_o + D_o$
117 and $N_h = S_h + E_h + I_h$); a indicates the rate of discharge of S_h from the hospital to the outside; u and g indicate the
118 non-infection and infection rates, respectively; C indicates the capacity of hospitals. We assumed that the
119 nature of the disease would determine these parameters; making them independent of hospitals both inside
120 and outside. r_j and d_j ($j \in \{o, h\}$) indicate the recovery and death rates from infection, respectively, where $r_o <$
121 r_h , and $d_o < d_h$; f and m indicate the rates of follow-up and mass-testing, corresponding to the extent to which
122 health centers follow exposed populations and take-up infected populations having symptoms, respectively;
123 Sp and Se indicate specificity and sensitivity, respectively, as testing characteristics. The model assumed that
124 I has a fixed proportion of symptomatic and asymptomatic individuals, and that symptomatic infected
125 individuals receive mass-testing. The sigmoid function $H(x) = 1/(1 + \exp(x))$ introduced the hospitalization
126 capacity. The parameter values and initial conditions are listed in Table 1 and discussed in the Materials and
127 Methods section.

128

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

A		C								
Variable	Value	Reference	Model	b	g	r_h	r_o	d_h	d_o	
S_h, E_h, I_h	1	Fang ²⁸	eSEIR	0.9 e-5 to e-6†	0.143	0.056	n/a	n/a	n/a	
I_o	97	Tang ²⁹	n/a	2.1 e-8	0.126	n/a	0.14	1.78 e-5	n/a	
S_o	999900	Kucharski ³⁰	eSEIR	n/a	0.156	n/a	n/a	n/a	n/a	
E_o, R_h, R_o, D_h, D_o	0	Backer ³¹	n/a	n/a	0.143 to 0.33	n/a	n/a	n/a	n/a	
		Bi Q ³²	n/a	n/a	n/a	n/a	n/a	n/a	n/a	
		Kuniya ³³	SEIR	0.2 e-8†	n/a	n/a	n/a	n/a	n/a	
		Linton ³⁴	n/a	n/a	0.2	n/a	n/a	n/a	n/a	
		Iwata ³⁶	SEIR	n/a	0.167 to 0.208	0.13 to 0.417	n/a	n/a	n/a	
		Sun ³⁷	vSIR	n/a	n/a	0.1	n/a	n/a	n/a	
		Rocklöv ³⁸	SEIR	0.4 e-4 or 0.12 e-4†	0.2	n/a	n/a	n/a	n/a	
		Roda ⁴³	SIR/SEIR	8.68 e-8	0.631	0.1	n/a	n/a	n/a	

B		C		D		
Mode of test	Se	Sp	Reference	Incubation period	Infectious period	
CT	0.98 ²⁸ , 0.97 ^{57,59} 0.8 to 0.9 ⁵⁰ , 0.972 ⁶¹	0.828 to 0.96 ⁶⁰	Kucharski ³⁰	5.2	2.9	
PCR	0.71 ²⁸ , 0.846 ⁶¹	n/a	Backer ³¹	6.5	n/a	
			Bi Q ³²	4.8	1.5	
			Wu ³⁵	6.1	2.3	
			Rocklöv ³⁸	5	10	
			Lin ⁴⁷	5.2	2.3	
			WHO-China Joint ⁴⁹	5.5	n/a	

Table 1: Variables and parameters in reports during the early stages of the pandemic


(A) Initial values for variables and parameters, (B) Reported sensitivity and specificity of the polymerase chain reaction (PCR) and CT for detecting COVID-19, Cells expressed as n/a indicate that we could not find the (C) reported transition parameters using models. Values with † are calculated from the original values for comparison. All values have a [one/day] dimension. We could not find values or models for the cells expressed as n/a. The values with † equal original values are divided by the total population, and (D) Reported incubation period and infectious periods. Each value has a [day] dimension.

129
130
131
132
133
134
135
136
137

138 **3 Results**

139 First, we examined the basic behavior of the testing-SEIRD model using simulations, as shown in Fig. 2.
140 Similar to the classical SEIRD model, the infection primarily expands, and infectious populations (I_h and I_o)
141 transiently increase in response to the presence of infectious people. Susceptible populations (S_h and S_o)
142 gradually decrease and change into recovered populations (R_h and R_o) through the exposed (E_h and E_o) and
143 infectious (I_h and I_o) states. During this process, the number of dead people increases gradually, as shown in
144 Fig. 2A. Because of hospital overcrowding, the outside and hospitalized populations decrease and increase in
145 response to testing, respectively, and their time courses are affected (Fig. 2B). The outside and hospitalized
146 populations are divided into five types of populations (susceptible, exposed, infectious, recovered, and dead)
147 (Figs. 2C and 2D). According to Fig. 2E, daily reports of positive tests and deaths transiently increase with
148 different peak timings, and the peak of positive tests precedes that of deaths.

149 To evaluate the speed of an infectious outbreak, we computed the basic reproduction number RN ,
150 which is the expected number of infections caused by one infected person until recovery (see Materials and
151 Methods). Reproduction numbers outside hospitals, RN_o , switches from greater than one to less than one
152 around the peak timing of infectious populations outside (Fig. 2F). Conversely, reproduction numbers inside
153 hospitals, RN_h , are less than one around the peak timing. This indicates that the infectious population in
154 hospitals increases owing to outside factors rather than an infectious spread within the hospitals. The testing-
155 SEIRD model recapitulates the basic infection dynamics of the total population as observed in the classical
156 SEIRD model (Fig. 2A) and enables us to examine the effect of the testing strategy and testing
157 characteristics with different populations inside and outside hospitals.



158


159 **Figure 2: Changes in components over time in the testing-SEIRD model**

160 Time-courses of (A) populations of all infectious states, irrespective of being inside and outside hospitals; (B)
161 populations inside and outside hospitals and dead populations, irrespective of infectious states; (C) populations of all
162 infectious states inside hospitals; (D) populations of all infectious states outside hospitals; (E) Daily reports of positive
163 test results, hospitalizations, and deaths; and (F) Time-courses of reproduction numbers inside and outside hospitals, as
164 described in Materials and Methods section.

165

166 To investigate the impact of hospitalization capacity on infection dynamics, such as daily reports of
167 positive test results, hospitalizations, and deaths, we simulated the testing-SEIRD model with various
168 capacities (Figs. 3A–3C). The results demonstrate that as the capacity increases, the maximum positive tests,

169 maximum hospitalizations, and cumulative deaths linearly decrease, increase, and decrease, respectively.
170 They all plateau at approximately 30% capacity (Figs. 3D–3F), and notches are observed to reflect the
171 capacity effect (Figs. 3B, 3D, 3E, 3F, 3G, 3H, and 3I). Additionally, we examined their peak timings and
172 found that they changed nonlinearly within certain time window ranges (Figs. 3G–3I). These results suggest
173 that the capacity change has a significant effect on the disease’s rate of spread but only a minor effect on
174 timing.
175



176
177 **Figure 3: Impact of hospitalization capacity on the three variables**
178 Time courses of (A) Daily reports of positive test results. (B) Daily reports of hospitalizations. (C) Daily reports of
179 deaths with varying hospitalization capacity. C/N indicates the capacity normalized to the total population.
180 Hospitalization capacity dependencies of (D) Maximum-positive reports. (E) Maximum hospitalizations. (F)
181 Cumulative deaths. Hospitalization capacity-dependencies of (G) Peak of daily reports of positive tests. (H) Peak of
182 hospitalizations. (I) Peak of daily deaths.

183
184 To illustrate the impact of the testing strategy on infectious outcomes, we examined the cumulative
185 deaths, maximum number of positive tests and hospitalizations, varying follow-up, and mass-testing rates.
186 The infectious spread shows an all-or-none response depending on the testing strategy (red and blue regions
187 in Fig. 4). Sensitivity analyses demonstrated the robust maintenance of such a profile regardless of the model
188 parameters (Figs. S1 and S2). The number of cumulative deaths was almost constant with a small amount of
189 both the follow-up and mass-testing (red region in panels in the first row of Fig. 4A); however, the
190 combination of follow-up and mass-testing successfully suppressed the infectious disease spread (blue region


191 in the panels in the first row of Fig. 4A). Furthermore, the maximum number of hospitalizations was
192 immediately saturated by either the follow-up or mass-testing because of the limited hospitalization capacity
193 (panels in the first row in Fig. 4B). The maximum number of positive tests increased more quickly with
194 follow-up testing compared with mass-testing (panels in the first row in Fig. 4C). According to statistics, the
195 number of cumulative deaths varied significantly depending on the strategies; there was a 724-fold
196 difference between the 90596 and 125 deaths at the optimal and worst strategies with a 1:1 cost ratio for
197 follow-up to mass-testing. Other infectious outcomes also depend on the strategies: there was a 466-fold
198 difference between 49424 and 106 hospitalizations and a 250-fold difference between 96525 and 135 daily
199 positive tests with the same cost ratio.

200 Subsequently, realistic scenarios were considered adapting to the limited resource L . Practically, the
201 follow-up and mass-testing rates cannot be controlled because of the limited medical resources for both
202 follow-up and mass-testing. Therefore, it is necessary to determine the amount of resources allocated to the
203 follow-up and mass-testing. Here, we consider all the possible decisions subject to the limited resource L as
204 follows:

$$L = c_f f + c_m m, \#(3.1)$$

205 where c_f and c_m indicate the costs for follow-up and mass-testing, respectively; f and m indicate the extent of
206 follow-up and mass-testing. We illustrated three lines using various L , c_f , and c_m , based on the disease,
207 economic, and technological situations of each country (panels in the first row of Fig. 4). The three colored
208 lines in the heat maps correspond to settings that are $L=500$, $c_f=1$, and $c_m=10$ in the green line; $L=300$, $c_f=1$,
209 and $c_m=5$ in the blue line; and $L=100$, $c_f=1$, and $c_m=1$ in the orange line, respectively. Given the total
210 amount of resources, we selected the optimal testing strategy on the line represented by Equation (3.1). We
211 demonstrated that the worst decisions (that is, the choice of f and m) significantly varied depending on the
212 situation (panels in the last row of Fig. 4).

213 Regarding the high resources and low ratio of the cost of follow-up testing to that of the mass-testing
214 cost, the number of cumulative deaths abruptly increases as the resource fraction of mass-testing exceeds
215 90% (green line in Fig. 4A). This indicates that the mass-dominant testing is the worst strategy for
216 minimizing the cumulative deaths. Conversely, the number of cumulative deaths abruptly decreases at the
217 resource fraction of 20–30% (blue line in Fig. 4A) assigned to mass-testing owing to low resource
218 availability and a high ratio of follow-up to mass-testing costs. Contrary to the previous case, this result
219 suggests that follow-up-dominant testing is the worst strategy. Regarding the intermediate situation between
220 the two cases above, the simulation showed a U-shape with the resource fraction assigned to mass-testing
221 ranging from approximately 10–80% (orange line in Fig. 4A). These results suggest that both follow-up and
222 mass-dominant testing strategies should be avoided. The choice of f and m also changed in the profiles of
223 maximum hospitalizations and positive reports (Figs. 4B and 4C). The optimal strategy for each
224 country/region depends on resource availability.




225

226 **Figure 4: Infectious spread based on the testing strategy**

227 The panels in the first row represent the number of (A) cumulative deaths, (B) maximum hospitalizations, and (C)
 228 maximum daily positive tests depending on the rates of follow-up and mass-testing. The three lines in these heatmaps
 229 represent the possible testing strategies subject to different total resources for testing with different ratios for the testing
 230 costs. $L=500$, $c_f=1$, and $c_m=10$ in the green line; $L=300$, $c_f=1$, and $c_m=5$ in the blue line; and $L=100$, $c_f=1$, and $c_m=1$ in
 231 the orange line. The panels in the second row represent the numbers along the three lines in the heatmaps. The panels in
 232 the third row represent semilog-plots of the second row.

233

234 Moreover, we examined the effects of the testing characteristics (that is, sensitivity and specificity)
 235 on the three variables (that is, the number of cumulative deaths, hospitalizations, and positive tests). We
 236 conducted sensitivity analyses for Se and Sp using values ranging from zero to four in 0.01 increments. We
 237 obtained almost the same heatmaps in the sensitivity-specificity space although the heatmaps were inverted
 238 along the x-axis (Fig. 5). The Equations (2.7), (2.8), (2.12), and (2.13) reveal that sensitivity and one-
 239 specificity essentially play the same roles in the follow-up and mass-testing. The sensitivity and specificity
 240 of the test cannot be changed, whereas the testing strategy can be arbitrary. If the sensitivity is low, an
 241 increase in the mass-testing rate can produce the same infectious result with high sensitivity. Conversely, if
 242 the specificity is low, a decrease in the follow-up testing rate can produce the same infectious result with
 243 high specificity. Therefore, we must manage the optimal testing strategy based on the testing sensitivity and
 244 specificity that cannot be changed.




245

246 **Figure 5: Infectious spread based on the testing properties**

247 Numbers of (A) Cumulative deaths, (B) Maximum hospitalizations, and (C) Maximum daily positive tests based on the
248 sensitivity and specificity of the testing.

249

250 We investigated how the infection is spread based on the testing strategy. However, this is from the
251 viewpoint of a perfect observer who knows the exact timeline of the latent populations. Practically, we were
252 unable to determine all the model variables, such as the exposed and infectious populations inside and
253 outside hospitals; however, we could merely monitor positive reports by follow-up and mass-testing. In this
254 study, we verified whether these two types of positive reports reflect the latent infectious population, which
255 is the most resource-consuming and challenging social issue. Using regression analysis (see Materials and
256 Methods), we demonstrate that latent infectious populations can be predicted from daily positive reports of
257 follow-up and mass-testing (Figs. 6A–6C). These results suggest that the infectious population is not only
258 proportional to the total number of follow-up and mass-testing positive results but also proportional to their
259 weighted sum (Fig. 6D). There are some situations where weights can be negative, depending on the model
260 parameters. We found that follow-up testing's weight for positive reports was negative with high positive
261 predictive values. This is because the negative weight of P_f represses the estimates of the latent number of
262 infectious people, reflecting a low positive predictive value (Fig. 6D).



263

264 **Figure 6: Prediction of infectious population from daily reports of positive test results**

265 (A-C) The Green and orange lines indicate the simulated and predicted infectious populations (I_h and I_o) with different
266 testing strategies. The linear regression $as w_f P_f + w_m P_m$, where w_f and w_m indicate the weights and P_f and P_m indicate the
267 daily positive reports of follow-up and mass-testing, namely, $f(I-Sp)$ and mSe , respectively, was used to estimate the
268 infectious populations. The least square method was used to estimate the weights. (D) The estimated weights for P_f and
269 P_m are plotted, considering various combinations of ratios of the follow-up cost to the mass-testing cost (P_f/P_m).

270

271

272 **4 Discussion**

273 ***Conclusion***

274 We developed a testing-SEIRD model with two discrete populations inside and outside hospitals, the
275 impact of testing strategy (follow-up testing [f], and mass-testing [m]), and testing characteristics (sensitivity
276 [Se] and specificity [Sp]) on three important variables (the number of maximum positive tests, maximum
277 hospitalizations, and cumulative deaths (Fig. 1)). By simulating the model with parameters representing the
278 early stages of the COVID-19 Alpha variant pandemic, we demonstrated that the optimal and the worst
279 testing strategies are subject to limited medical resources (Fig. 4). Additionally, we highlighted the
280 possibility that the infectious population can be predicted by a weighted sum of positive follow-up and mass-
281 testing reports (Fig. 6).

282

283 ***4-1 Related work***

284 Infectious dynamics models, such as SEIRD models and their alternatives, which have been widely
285 used for policy making through model simulation, are abundant [1,26-46]. Although some of the previous
286 models included a hospital compartment [1,26-28,30,34], they did not consider the testing strategy and
287 testing characteristics. Our model assumes that in certain models, the exposed people do not infect the
288 susceptible ones but they end up being affected [1,26-38]. All models, except the model with intervention
289 strategies, [39] did not consider the testing cost. Similar to our model, three studies modeled the control of
290 infectious outbreaks, which addressed the possibility of an optimal solution for controlling infectious
291 outbreaks [39], the stable situation depending on the proportion of the susceptible population [40], and the
292 basic reproduction number depending on contact rate [43]. However, to the best of our knowledge, no model
293 has been developed that considers the effects of both testing characteristics and limited medical resources on
294 the number of deaths. Consequently, our testing-SEIRD model introduced new factors: the hospital
295 compartment, testing strategy, testing characteristics, and medical resources, compared with the previous
296 SEIRD model (Figs. 2–4). The testing-SEIRD model also comprehensively encompasses the classical
297 SEIRD model, which corresponds to the condition where f and m are both zero.

298

299 ***4-2 Model prediction***

300 Our model has three advantages. First, the testing-SEIRD model provides the optimal testing
301 strategy for various situations. The model provides heatmaps based on the three variables' numbers in the
302 space of the testing strategy (Fig. 4). These heatmaps indicate the best direction, which is shown by the blue
303 region in Fig. 4. This corresponds to the settling of infections using the shortest path. Second, the testing-
304 SEIRD model can predict the optimal and worst strategies, considering the limited medical resources and
305 ratios for the testing costs (Fig. 4). Because the total costs of medical resources and testing depend on the

306 country, our model provides an optimal testing strategy unique to each country. Third, the testing-SEIRD
307 model demonstrates that the latent number of infectious populations can be predicted from daily positive
308 reports of the follow-up and mass-testing (Fig. 6).

309

310 **4-3 Validity of the model components**

311 Here, we discuss the validity of the model components, which is not factored by the previous models.
312 First, we focus on the transition from E_e to E_i (Fig. 1). We assume that the follow-up testing causes the
313 hospitalization of the exposed population. Populations who have only recently been exposed but have not yet
314 developed symptoms do not participate in the tests. They only test when the follow-up encourages them.
315 Second, in relation to the transition from I_e to I_i , we assume that the mass-testing causes the hospitalizations
316 of the infectious population, which is defined as a person with symptoms. In our model, we address the rate
317 of mass-testing as a modifiable parameter because the rate depends on the volume of tests, such as PCR and
318 the degree of social penalty if it is positive. Third, we consider the transition from E_e to S_e and E_i to S_i . In our
319 model, all the exposed populations are not necessarily infected and some return susceptible compared with
320 the previous models, which assume that all exposed populations are destined to be infected [28,30,32,33,35-
321 38,47-49]. Consistent with our model, some exposed populations return to susceptible populations without
322 developing symptoms. Finally, because the above-mentioned assumptions regarding exposure, infection, and
323 hospitalization processes are common in VOCs, our model is not specific to the Alpha variant but is
324 applicable to other VOCs [8]. Combining new components and the testing-SEIRD model is consistent with
325 the previous simulation model and reflects and incorporates a practical viewpoint.

326

327 **4-4 Validity of the model parameters**

328 We used parameters from earlier reports before the Beta variant emerged in South Africa in May
329 2020 [8] (Table 1) because the earlier reports contained homogeneous Alpha variant data. After May 2020,
330 the reports present an inhomogeneous mixture of multiple variants. A sensitivity analysis was performed
331 after setting the sensitivity and specificity of testing to 0.7 each, as shown in (Fig. 4). The results were
332 robustly guaranteed. The incubation and infectious periods remained roughly stable in VOCs, while the
333 number of reproductions and mortality rates differed among variants [8,12,14]. A sensitivity analysis of b
334 and u provided a robust guarantee for the number of reproductions and reinfections [42] effects (Fig. S1).
335 Mortality was considered in the model with d_e and d_i and these values were sensitivity analyzed (Fig. S2). A
336 sensitivity analysis robustly guaranteed a or the rate of discharge from S_e (Fig. S3). Although these values
337 are based on the COVID-19 Alpha variant, our sensitivity analysis indicates that the testing-SEIRD model
338 robustly generated the optimal and worst testing strategies for other VOCs with different parameters.

339 Our model does not assign a specific value to the basic reproduction number even though it is one of
340 the most crucial variables in infectious diseases [39,51,52]. Instead, it is only obtained using Equations (5.1)

341 to (5.3). This is permissive because the reproduction number depends on the exposure rate (b) [43], and we
342 performed a sensitivity analysis for the value of b (Fig. S1).

343

344 **4-5 Future studies**

345 Considering the future perspectives of our model, first, our testing-SEIRD model only simulates an
346 infection's single peak time course. However, we observed several COVID-19 infection peaks in many
347 countries [53]. To incorporate the multiple peaked dynamics, we must introduce the socio-psychological
348 effects caused by policies such as lockdown and social distancing. Second, our model assumes that all
349 populations are homogeneous and does not address stratification based on attributes such as gender, age,
350 social activities, and comorbidities [54,55]. Future research should consider this perspective. Finally, our
351 model did not include the effects of vaccination. There are current efforts to fight the spread of COVID-19
352 using messenger RNA (mRNA) vaccines. Our results appear favorable; however, we do not know the
353 duration of the effect of the vaccinations or the effectiveness of the acquired immunity against VOCs
354 [53,56,57]. Therefore, the tug-of-war between the evolution of vaccines and the spread of virus remains
355 elusive.

356

357 **5 Materials and Methods**

358 **5-1 Parameter set**

359 The parameters and initial conditions of the simulation are listed in Table 1A. We used parameters
360 from the COVID-19 Alpha variant studies. The total population N was set to 1,000,000 according to the
361 United Nations statistical papers: The World's Cities in 2018 states that one in five people worldwide live in
362 a city with more than one million inhabitants, and the median value of inhabitants is between 500,000 and
363 one million [58]. Therefore, sensitivity Se and specificity Sp were both set to 0.7, corresponding to those of
364 the PCR for detecting COVID-19 (Table 1B) [28,47,58-61]. The values of b , g , r_h , r_o , and d_h are based on
365 previous reports (Table 1C) [3,29–34,36–38,50]. The sum of u and g is the inverse of the incubation period
366 during the exposed state, which is reportedly five days (Table 1C) [31–33,49,60]. The sum of r and d is the
367 inverse of the infectious period during the infectious state, which is reportedly ten days (Table 1D)
368 [31,32,35,60].
369

370 **5-2 Definitions of reproduction numbers**

371 We computed the time courses of the reproduction numbers inside and outside hospitals (RN_h and
372 RN_o) using Fig. 2.

$$RN_h = \frac{1}{r_h + d_h} \cdot \frac{bS_h}{S_h + E_h + I_h} \cdot \frac{g}{u + g}, \#(5.1)$$

$$RN_o = \frac{1}{r_o + d_o} \cdot \frac{bS_o}{S_o + E_o + I_o + R_o + R_h} \cdot \frac{g}{u + g}. \#(5.2)$$

373 Here, the first, second, and third factors in these equations indicate the average infectious period, infection
374 rate, and probability that the exposed state transits to the infectious state, respectively. The reproduction
375 number in the classical SEIRD model was defined in previous studies [1,27–34] as follows:

$$RN = \frac{1}{r + d} \cdot \frac{bS}{S + E + I + R}. \#(5.3)$$

376

377 **5-3 Code and data availability**

378 All codes and data required to reproduce the results of this study are hosted in Github at
379 <https://github.com/bougtoir/testing-SEIRD>. The Github repository contains Jupyter notebooks for Runge-
380 Kutta method differential equations and their visualization. The python codes described in the Jupyter
381 notebooks can reproduce all figures in this study without the need for external files or settings.
382

383

384 **Acknowledgments**

385 We thank Tomohiko Takada M.D. (Ph.D.) and Yoshika Onishi M.D. (Ph.D.) for providing the basic concepts of
386 clinical NNT. We thank Yoshiaki Yamagishi M.D. (Ph.D.), Tomokazu Doi M.D. (Ph.D.), and Tatsuyoshi Ikenoue
387 M.D. (Ph.D.) for revising the early manuscript. We also acknowledge Prof. Hiroshi Nishiura for organizing a
388 summer boot camp in 2014 to provide fundamental knowledge on infectious disease modeling.

389

390 **Funding**

391 This study was partly supported by the Cooperative Study Program of Exploratory Research Centre on Life and
392 Living Systems (ExCELLS) (program Nos.18-201, 19-102, and 19-202 to H.N.), a Grant-in-Aid for
393 Transformative Research Areas (B) [grant number 21H05170], and a Grant-in-Aid for Scientific Research (B)
394 (21H03541 to H.N.) from the Japan Society for the Promotion of Science (JSPS).

395

396 **Ethics**

397 This study did not involve human or animal subjects.

398

399 **Author Contributions**

400 O.T. and Y.I. conceived the initial ideas. O.T. developed and implemented the method, processed, and analyzed
401 the data, and wrote the initial draft of the manuscript. H.N. revised the initial draft of the manuscript and reviewed
402 the method. Y.I. supervised the project. All authors contributed to the final writing of the manuscript.

403

404 **Competing Interests**

405 The authors declare no competing interests.

406

407

References

408

409

1. Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. . COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. 2020;24:;91–98. doi:10.1016/j.jare.2020.03.005

410

411

2. Kolifarhood G, Aghaali M, Saadati HM, Taherpour N, Rahimi S, Izadi N, Saeed S, Nazari H. .

412

Epidemiological and Clinical Aspects of COVID-19; a Narrative Review. 2020;8,41.

413

doi:10.22037/AAEM.V8I1.620

414

3. Johns Hopkins Coronavirus Resource Center. COVID-19 Map In [Internet] Johns Hopkins

415

Coronavirus Resource Center; [cited 21May.2020]. Available:

416

<https://coronavirus.jhu.edu/map.html>

417

4. GitHub - owid/covid-19-data: Data on COVID-19 (coronavirus) cases, deaths, hospitalizations,

418

tests • All countries • Updated daily by Our World in Data. In: [Internet]. Our world in Data ; [cited

419

31March.2022] Available: <https://github.com/owid/covid-19-data>

420

5. 2021 COVID Data Tracker, Centers for Disease Control and Prevention. In: [Internet]. Centers for

421

Disease Control and Prevention. [cited 31March.2022] Available: [https://covid.cdc.gov/covid-data-](https://covid.cdc.gov/covid-data-tracker/#datatracker-home)

422

[tracker/#datatracker-home](https://covid.cdc.gov/covid-data-tracker/#datatracker-home)

423

6. Coronavirus disease 2019 (COVID-19) Situation Report – 46 . In: [Internet]. World Health

424

Organization; [cited 31March.2022]. Available: [https://www.un.org/unispal/document/coronavirus-](https://www.un.org/unispal/document/coronavirus-disease-2019-covid-19-situation-report-46/)

425

[disease-2019-covid-19-situation-report-46/](https://www.un.org/unispal/document/coronavirus-disease-2019-covid-19-situation-report-46/)

426

7. 2020 Laboratory testing strategy recommendations for COVID-19. In: [Internet]. World Health

427

Organization; [cited 31March.2022]. Available:

428

[https://apps.who.int/iris/bitstream/handle/10665/331509/WHO-COVID-19-lab_testing-2020.1-](https://apps.who.int/iris/bitstream/handle/10665/331509/WHO-COVID-19-lab_testing-2020.1-eng.pdf)

429

[eng.pdf](https://apps.who.int/iris/bitstream/handle/10665/331509/WHO-COVID-19-lab_testing-2020.1-eng.pdf).

430

8. Tracking-SARS-CoV-2-variants. In: [Internet]. World Health Organization; [cited 31March.2022].

431

Available <https://www.who.int/en/activities/tracking-SARS-CoV-2-variants>

432

9. Joebges S, Biller-Andorno N. Ethics guidelines on COVID-19 triage - An emerging international

433

consensus. 2020;24, 1–5. doi:10.1186/s13054-020-02927-1

434

10. Yan Bai, MD Lingsheng Yao, MD TaoWei, MD Fei Tian, MD Dong-Yan Jin, PhD Lijuan Chen,

435

PhD MeiyunWang, MD P. Letters Presumed Asymptomatic Carrier Transmission of COVID-19.

436

2020;323(14): 1406-1407 doi:10.1001/jama.2020.2565

437

11. Al-Sadeq DW, Nasrallah GK. The incidence of the novel coronavirus SARS-CoV-2 among

438

asymptomatic patients: A systematic review. 2020; 98, 372–380. doi:10.1016/j.ijid.2020.06.098

439

12. Mallett S et al. At what times during infection is SARS- CoV-2 detectable and no longer

440

detectable using RT-PCR-based tests? A systematic review of individual participant data.

441

2020;18, 1–17. doi:10.1186/s12916-020-01810-8

442

13. Yukari C. Manabe M, Joshua S. Sharfstein M, Katrina Armstrong M. The Need for More and

443

Better Testing for COVID-19. 2020;324(21): 2153-2154. doi:10.1001/jama.2020.21694


- 444 14. Rhee C, Kanjilal S, Baker M, Klompas M. Duration of Severe Acute Respiratory Syndrome
445 Coronavirus 2 (SARS-CoV-2) Infectivity: When Is It Safe to Discontinue Isolation? 2021;72,
446 1467–1474. doi:10.1093/cid/ciaa1249
- 447 15. Wilson E, Donovan C V, Campbell M. Multiple COVID-19 Clusters on a University Campus -
448 North Carolina, August 2020;69, 1416–1418. doi: 10.15585/mmwr.mm6939e3
- 449 16. Id VB, Mallein B. Group testing as a strategy for COVID-19 epidemiological monitoring and
450 community surveillance. 2021;17, 1–25. doi:10.1371/journal.pcbi.1008726
- 451 17. Testing for COVID-19: A way to lift confinement restrictions. In: [Internet]. Organisation for
452 Economic Cooperation and Development; [cited 31March.2022]. Available: [https://read.oecd-](https://read.oecd-ilibrary.org/view/?ref=129_129658-l62d7lr66u&title=Testing-for-COVID-19-A-way-to-lift-confinement-restrictions)
453 [ilibrary.org/view/?ref=129_129658-l62d7lr66u&title=Testing-for-COVID-19-A-way-to-lift-](https://read.oecd-ilibrary.org/view/?ref=129_129658-l62d7lr66u&title=Testing-for-COVID-19-A-way-to-lift-confinement-restrictions)
454 [confinement-restrictions](https://read.oecd-ilibrary.org/view/?ref=129_129658-l62d7lr66u&title=Testing-for-COVID-19-A-way-to-lift-confinement-restrictions).
- 455 18. Signorini SG, Brugnoli D. Less is more □: an ecological and economic point of view on
456 appropriate use of lab testing for COVID patients. 2021;24, 781-1783. doi:10.4155/bio-2021-0064
- 457 19. Overview of testing for SARS-CoV-2 (COVID-19). In: [Internet]. Centers for Disease Control and
458 Prevention; [cited 29August.2020]. Available: [https://www.cdc.gov/coronavirus/2019-](https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html)
459 [ncov/hcp/testing-overview.html](https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html)
- 460 20. Id DRB, Bish EK, El-hajj H, Aprahamian H. A robust pooled testing approach to expand COVID-
461 19 screening capacity.2021;16(2), 1-15. doi:10.1371/journal.pone.0246285
- 462 21. Thought on COVID-19 testing. In: [Internet]. Japanese society of pediatrics; [cited 21May.2020].
463 Available: http://www.jpeds.or.jp/modules/activity/index.php?content_id=329
- 464 22. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 16 March 2020.
465 In: [Internet]. World Health Organization; [cited 21May.2020]. Available:
466 [https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-](https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---16-march-2020)
467 [the-media-briefing-on-covid-19---16-march-2020](https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---16-march-2020)
- 468 23. Godlee F. The burning building. 2020;368, m1101. doi:10.1136/bmj.m1101
- 469 24. Peto J. Covid-19 mass testing facilities could end the epidemic rapidly. 2020; 368, m1163.
470 doi:10.1136/bmj.m1163
- 471 25. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases. In:
472 [Internet]. World Health Organization; [cited 31March.2022]. Available:
473 <https://www.who.int/publications/i/item/10665-331501>
- 474 26. Gerardo C, Lisa S, Shweta B, Cécile V. Mathematical models to characterize early epidemic
475 growth: A Review. 2018;176, 139–148. doi:10.1016/j.pprev.2016.07.005.Mathematical
- 476 27. Roguski KM et al. Estimates of global seasonal influenza-associated respiratory mortality: a
477 modelling study. 2019; 391, 1285–1300. doi:10.1016/S0140-6736(17)33293-2
- 478 28. Fang Y, Nie Y, Penny M. Transmission dynamics of the COVID-19 outbreak and effectiveness of
479 government interventions: A data-driven analysis. 2020;92(6), 645-659. doi:10.1002/jmv.25750

- 480 29. Tang B, Bragazzi NL, Li Q, Tang S, Xiao Y, Wu J. An updated estimation of the risk of
481 transmission of the novel coronavirus (2019-nCov). 2020; 5, 248–255.
482 doi:10.1016/j.idm.2020.02.001
- 483 30. Kucharski AJ et al. Early dynamics of transmission and control of COVID-19: a mathematical
484 modelling study. 2020; 20, 553–558. doi:10.1016/S1473-3099(20)30144-4
- 485 31. Backer J, Klinkenberg D, Wallinga J. The incubation period of 2019-nCoV infections among
486 travellers from Wuhan, China. 2020;25(5):pii=2000062. doi:10.2807/1560-
487 7917.ES.2020.25.5.2000062
- 488 32. Bi Q et al. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close
489 contacts in Shenzhen, China: a retrospective cohort study. 2020;20, 911–919. doi:10.1016/S1473-
490 3099(20)30287-5
- 491 33. Kuniya T. Prediction of the Epidemic Peak of Coronavirus Disease in Japan, 2020. 2020;9(3).
492 doi:10.3390/jcm9030789
- 493 34. Linton NM, Kobayashi T, Yang Y, Hayashi K, Akhmetzhanov AR, Jung SM, Yuan B, Kinoshita R,
494 Nishiura H. Incubation period and other epidemiological characteristics of 2019 novel coronavirus
495 infections with right truncation: A statistical analysis of publicly available case data. 2020;9, 538.
496 doi:10.1101/2020.01.26.20018754
- 497 35. Joseph TW, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and
498 international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study.
499 2020;395, 689–697. doi:10.1016/S0140-6736(20)30260-9
- 500 36. Iwata K, Miyakoshi C. A Simulation on Potential Secondary Spread of Novel Coronavirus in an
501 Exported Country Using a Stochastic Epidemic SEIR Model. 2020;9, 944.
502 doi:10.3390/jcm9040944
- 503 37. Sun H, Qiu Y, Yan H, Huang Y, Zhu Y, Gu J, Chen S. Tracking Reproductivity of COVID-19
504 Epidemic in China with Varying Coefficient SIR Model. 2021;B, 455–472.
505 doi:10.6339/jds.202007_18(3).0010
- 506 38. Rocklöv J, Sjödin H, Wilder-Smith A. COVID-19 outbreak on the diamond princess cruise ship:
507 Estimating the epidemic potential and effectiveness of public health countermeasures. 2021;27, 1–
508 7. doi:10.1093/JTM/TAAA030
- 509 39. Mondal J., Khajanchi S. Mathematical modeling and optimal intervention strategies of the
510 COVID-19 outbreak. 2022;109, 177-202. doi:10.1007/s11071-022-07235-7
- 511 40. Khajanchi S., Sarkar K., Banerjee S. Modeling the dynamics of COVID-19 pandemic with
512 implementation of intervention strategies. 2022;137, 129. doi:10.1140/epjp/s13360-022-02347-w
- 513 41. Tiwari, P. K., Rai, R. K., Khajanchi, S., Gupta, R. K., & Misra, A. K. Dynamics of coronavirus
514 pandemic: effects of community awareness and global information campaigns. 2021;136(10), 994.
515 doi:10.1140/epjp/s13360-021-01997-6

- 516 42. Khajanchi, S., Sarkar, K., Mondal, J., Nisar, K. S., & Abdelwahab, S. F. Mathematical modeling of
517 the COVID-19 pandemic with intervention strategies. 2021;25, 104285.
518 doi:10.1016/j.rinp.2021.104285
- 519 43. Sarkar, K., Khajanchi, S., & Nieto, J. J. Modeling and forecasting the COVID-19 pandemic in
520 India. 2020;139, 110049. doi:10.1016/j.chaos.2020.110049
- 521 44. Khajanchi, S., & Sarkar, K. Forecasting the daily and cumulative number of cases for the COVID-
522 19 pandemic in India. 2020;30(7), 071101. doi:10.1063/5.0016240
- 523 45. Samui, P., Mondal, J., & Khajanchi, S. A mathematical model for COVID-19 transmission
524 dynamics with a case study of India. 2020;140, 110173. doi:10.1016/j.chaos.2020.110173
- 525 46. Rai, R. K., Khajanchi, S., Tiwari, P. K., Venturino, E., & Misra, A. K. Impact of social media
526 advertisements on the transmission dynamics of COVID-19 pandemic in India. 2022;68(1), 19–44.
527 doi:10.1007/s12190-021-01507-y
- 528 47. Lin L et al. Using Artificial Intelligence to Detect COVID-19 and Community-acquired Pneumonia
529 Based on Pulmonary CT: Evaluation of the Diagnostic Accuracy. 2020;296(2), E65-E71.
530 doi:10.1148/radiol.2020200905
- 531 48. Roda WC, Varughese MB, Han D, Li MY. Why is it difficult to accurately predict the COVID-19
532 epidemic? 2020;5, 271–281. doi:10.1016/j.idm.2020.03.001
- 533 49. 2020 China Joint Mission on Coronavirus Disease 2019 (COVID-19). World health organization.
534 2019, 16–24. In: [Internet]. World Health Organization; [cited 21 May 2020]. Available
535 [https://www.who.int/publications/i/item/report-of-the-who-china-joint-mission-on-coronavirus-](https://www.who.int/publications/i/item/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19))
536 [disease-2019-\(covid-19\)](https://www.who.int/publications/i/item/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19))
- 537 50. Pulliam JRC, van Schalkwyk C, Govender N, von Gottberg A, Cohen C, Groome MJ, Dushoff J,
538 Mlisana K, Moultrie H. Increased risk of SARS-CoV-2 reinfection associated with emergence of
539 Omicron in South Africa. *Science* 2022; 376, 1–43. doi:10.1126/science.abn4947
- 540 51. Lu, X., Hui, L., Liu, S., & Li, J. A mathematical model of HTLV-I infection with two time delays.
541 2015;12(3), 431–449. doi:10.3934/mbe.2015.12.431
- 542 52. Wang, L., Li, M. Y., & Kirschner, D. Mathematical analysis of the global dynamics of a model for
543 HTLV-I infection and ATL progression. 2002;179(2), 207–217. doi:10.1016/s0025-
544 5564(02)00103-7
- 545 53. GISAID - Initiative. In: [Internet]. GISAID; [cited 9 May 2021]. Available <https://www.gisaid.org>
- 546 54. Shahid Z et al. COVID-19 and Older Adults: What We Know. 2020;68, 926–929.
547 doi:10.1111/jgs.16472
- 548 55. Thomas DM, Sturdivant R, Dhurandhar N v., Debroy S, Clark N. A Primer on COVID-19
549 Mathematical Models. 2020;28, 1375–1377. doi:10.1002/oby.22881
- 550 56. Sharp TM et al. Antibody Persistence through 6 Months after the Second Dose of mRNA-1273
551 Vaccine for Covid-19. 2021; 384, 2257–2259. doi:10.1056/nejmc2023298
- 552 57. Christian HH, Daniela M, Sophie MG, Kåre M, Steen E. Assessment of protection against
553 reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a

- 554 population-level observational study Christian. 2020;397(10280), 1204-1212. doi:10.1016/ S0140-
555 6736(21)00575-4
- 556 58. United Nations. 2018 The World's Cities in 2018: Data Booklet. doi:10.18356/C93F4DC6-EN
- 557 59. Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, Tao Q, Sun Z, Xia L. Correlation of Chest CT and
558 RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases.
559 2020;296(2), E32-E40200642. doi:10.1148/radiol.2020200642
- 560 60. Long C et al. Diagnosis of the Coronavirus disease (COVID-19): rRT-PCR or CT?
561 2020;126,108961. doi:10.1016/j.erad.2020.108961
- 562 61. Lai S et al. Effect of non-pharmaceutical interventions to contain COVID-19 in China. 2021;585,
563 410–413. doi:10.1038/s41586-020-2293-x.Effect
- 564
- 565

566 **Supporting information**




567

568 **Figure S1: Sensitivity analyses of parameters b and u on the number of cumulative deaths**

569 Simulations were performed using different values of b and u .

570

571



572

573

Figure S2: Sensitivity analyses of d_o and d_h on the number of cumulative deaths

574

Simulations were performed using different values of d_o and d_h , where (d_o, d_h) of $(0.01, 0.007)$ is a reference standard;

575


$(0.01, 0.001)$ means advance in treatment; $(0.01, 0.01)$ means futile treatment; and $(0.001, 0.0007)$ means reduction in

576

overall mortality.

577

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .



578

579

Figure S3: Sensitivity analyses of parameter a on the number of cumulative deaths

580

Simulations were performed using different values of parameter a .

581